| 000 | 01641 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250516062355.0 | ||
| 264 | 0 | _c20120727 | |
| 008 | 201207s 0 0 eng d | ||
| 022 | _a1432-0843 | ||
| 024 | 7 |
_a10.1007/s00280-011-1773-y _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aReardon, David A | |
| 245 | 0 | 0 |
_aRidaforolimus for patients with progressive or recurrent malignant glioma: a perisurgical, sequential, ascending-dose trial. _h[electronic resource] |
| 260 |
_bCancer chemotherapy and pharmacology _cApr 2012 |
||
| 300 |
_a849-60 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntibiotics, Antineoplastic _xadverse effects |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 | _aCombined Modality Therapy |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGlioma _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunohistochemistry |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMaximum Tolerated Dose |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aSirolimus _xadverse effects |
| 700 | 1 | _aWen, Patrick Y | |
| 700 | 1 | _aAlfred Yung, W K | |
| 700 | 1 | _aBerk, Lori | |
| 700 | 1 | _aNarasimhan, Narayana | |
| 700 | 1 | _aTurner, Christopher D | |
| 700 | 1 | _aClackson, Timothy | |
| 700 | 1 | _aRivera, Victor M | |
| 700 | 1 | _aVogelbaum, Michael A | |
| 773 | 0 |
_tCancer chemotherapy and pharmacology _gvol. 69 _gno. 4 _gp. 849-60 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s00280-011-1773-y _zAvailable from publisher's website |
| 999 |
_c21268680 _d21268680 |
||